IGF1R and Ewing sarcoma: Consequently, multiple clinical attempts have been made to inhibit IGF-1R signaling (15–33) with collective analysis of data from phase I and II clinical trials targeting this pathway in ES, having demonstrated a response rate of 10-14% (34, 35).